Skip to main content

Table 1 Demographics and clinical characteristics of patients in the CIK treatment and Control groups

From: PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer

Clinicopathologic variables Control Group (n = 160) CIK Treatment Group (n = 150) p value
Age (y)    0.685
  <  50 59 52  
  ≥ 50 101 98  
Tumor size (mm)    0.500
  <  20 76 77  
  ≥ 20 84 73  
TNM stage    0.849
 I 19 15  
 II 66 65  
 III 75 70  
Histological differentiation    0.905
 I/II 96 89  
 III 64 61  
Positive lymph node ratio    0.628
 < 0.21 59 50  
 0.21 ≤ x <  0.65 80 75  
 ≥0.65 21 25  
Receptor status    
 ER    0.602
  Positive 51 52  
  Negative 109 98  
 PR    0.877
  Positive 75 69  
  Negative 85 81  
 Her2    0.604
  Positive 60 52  
  Negative 100 98  
PD-L1 expression    0.264
 Positive 42 44  
 Negative 118 106  
Chemotherapy    0.549
 Yes 150 138  
 No 10 12  
Radiotherapy    0.267
 Yes 149 144  
 No 11 6  
Endocrinetherapy    0.136
 Yes 109 90  
 No 51 60  
TNBC    0.952
 Yes 26 24  
 No 134 126